Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Fuji
Boehringer Ingelheim
Merck
Moodys
Federal Trade Commission
Johnson and Johnson
AstraZeneca
Chinese Patent Office

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021774

« Back to Dashboard

NDA 021774 describes AMBIEN CR, which is a drug marketed by Sanofi Aventis Us and is included in one NDA. It is available from eleven suppliers. There is one patent protecting this drug and two Paragraph IV challenges. Additional details are available on the AMBIEN CR profile page.

The generic ingredient in AMBIEN CR is zolpidem tartrate. There are thirty-two drug master file entries for this compound. Sixty-five suppliers are listed for this compound. Additional details are available on the zolpidem tartrate profile page.
Summary for 021774
Tradename:AMBIEN CR
Applicant:Sanofi Aventis Us
Ingredient:zolpidem tartrate
Patents:1
Therapeutic Class:Sedatives/Hypnotics
Formulation / Manufacturing:see details
Pharmacology for NDA: 021774
Ingredient-typePyridines
Mechanism of ActionGABA A Agonists
Physiological EffectCentral Nervous System Depression
Suppliers and Packaging for NDA: 021774
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
AMBIEN CR zolpidem tartrate TABLET, EXTENDED RELEASE;ORAL 021774 NDA sanofi-aventis U.S. LLC 0024-5501 N 0024-5501-10
AMBIEN CR zolpidem tartrate TABLET, EXTENDED RELEASE;ORAL 021774 NDA sanofi-aventis U.S. LLC 0024-5501 N 0024-5501-31

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength12.5MG
Approval Date:Sep 2, 2005TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jun 1, 2020Product Flag?Substance Flag?Delist Request?Y

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, EXTENDED RELEASE;ORALStrength6.25MG
Approval Date:Sep 2, 2005TE:ABRLD:Yes
Patent:➤ Sign UpPatent Expiration:Jun 1, 2020Product Flag?Substance Flag?Delist Request?Y

Expired US Patents for NDA 021774

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us AMBIEN CR zolpidem tartrate TABLET, EXTENDED RELEASE;ORAL 021774-001 Sep 2, 2005 ➤ Sign Up ➤ Sign Up
Sanofi Aventis Us AMBIEN CR zolpidem tartrate TABLET, EXTENDED RELEASE;ORAL 021774-002 Sep 2, 2005 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Daiichi Sankyo
McKinsey
Cerilliant
Citi
Fish and Richardson
US Department of Justice
Queensland Health
Healthtrust
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.